Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

References

• Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540–59
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-80
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum 2004;17:183-90
   Google Scholar
• BYETTA® (exenatide) Injection [prescribing information]. San Diego, CA: Amlyin Pharmaceuticals, Inc., 2011
   Google Scholar
• Deyoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in Poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145-54
   PubMed Web of Science ®Google Scholar
• Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011;50:65-74
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(1 Suppl):S27-40
   PubMed Web of Science ®Google Scholar
• Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638–46
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262–5
   Google Scholar
• Woodroffe R, Yao GL, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005;9:1-179, iii–iv
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004;19:1594-9
   PubMed Web of Science ®Google Scholar
• Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
   PubMed Web of Science ®Google Scholar
• Sharma S, Oliver-Fernandez A, Bakal J, et al. Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Opthamol 2003;87:259-61
   PubMed Web of Science ®Google Scholar
• Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004;30:549-56
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24
   PubMed Web of Science ®Google Scholar
• Hopkins RB, Tarride JE, Bowen J, et al. Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Can J Ophthalmol 2008;43:213-7
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
   PubMed Web of Science ®Google Scholar
• PriceRx Medispan Wholesale Acquisition Costs (WAC). 2010. http://www.medi–span.com/index.aspx. Accessed January 1, 2010
   Google Scholar
• Consumer Price Index for Medical Care Services. US Department of Labor, Bureau of Labor Statistics. 2006. http://www.bls.gov/cpi. Accessed July 1, 2010
   Google Scholar
• U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
   PubMed Web of Science ®Google Scholar
• Beaudet A, Wilson B, Caputo J, et al. Projected long-term clinical and economic outcomes of exenatide once weekly versus sitagliptin for the treatment of type 2 diabetes in the UK [abstract]. Value Heath 2011;14:A476
   Google Scholar
• Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995;311:1595-9
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008;6:103-12
   PubMedGoogle Scholar
• O’Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38
   PubMed Web of Science ®Google Scholar